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OBJECTIVE
To evaluate serum amylase and lipase levels and the rate of acute pancreatitis in
patients with type 2 diabetes and high cardiovascular risk randomized to liraglutide
or placebo and observed for 3.5–5.0 years.
RESEARCH DESIGN AND METHODS
A total of 9,340patientswith type2diabeteswere randomized toeither liraglutideor
placebo (median observation time 3.84 years). Fasting serum lipase and amylase
were monitored. Acute pancreatitis was adjudicated in a blinded manner.
RESULTS
Compared with the placebo group, liraglutide-treated patients had increases in se-
rum lipase and amylase of 28.0% and 7.0%, respectively. Levels were increased at
6 months and then remained stable. During the study, 18 (0.4% [1.1 events/1,000
patient-years of observation] [PYO]) liraglutide-treated and 23 (0.5% [1.7 events/
1,000 PYO]) placebo patients had acute pancreatitis confirmed by adjudication.Most
acutepancreatitis casesoccurred‡12months after randomization. Liraglutide-treated
patients with prior history of pancreatitis (n = 147) were not more likely to develop
acute pancreatitis than similar patients in the placebo group (n = 120). Elevations of
amylase and lipase levels did not predict future risk of acute pancreatitis (positive
predictive value <1.0%) in patients treated with liraglutide.
CONCLUSIONS
In a population with type 2 diabetes at high cardiovascular risk, there were numer-
ically fewer events of acute pancreatitis among liraglutide-treated patients (regard-
less of previous history of pancreatitis) comparedwith the placebo group. Liraglutide
was associated with increases in serum lipase and amylase, which were not pre-
dictive of an event of subsequent acute pancreatitis.
Glucagon-like peptide 1 (GLP-1) receptor agonists are established glucose-lowering
drugs for treating type 2 diabetes (1). However, incretin-based therapies (GLP-1 re-
ceptor agonists and dipeptidyl peptidase 4 [DPP-4] inhibitors) are associated with
increased levels of serum lipase and amylase, and a potential for an increased risk of
acute pancreatitis has previously been raised (2–6). Current assessments from regula-
tory agencies in Europe and the U.S. indicate that pancreatitis should be considered a
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risk associated with incretin-based drugs
until further data are available (7). Sub-
sequently, analyses of pooled data from
shorter phase III clinical trials of GLP-1 re-
ceptor agonists have noted an associa-
tion with 38 cases of acute pancreatitis
among 17,775 patient-years of observa-
tion (PYO) (event rate 2.1/1,000 PYO)
compared with 9 cases after 5,863 PYO
(event rate 1.5/1,000 PYO) (8). For DPP-4
inhibitors, thoughmeta-analysis of shorter
regulatory trials failed to show an associ-
ation with pancreatitis (8), meta-analysis
of the longer cardiovascular outcomes tri-
als does suggest a small increased risk
(9,10).
Due to the previous results and the lack
of long-term data, pancreatitis continues
to be of interest in studies of GLP-1 re-
ceptor agonists, particularly in studies
where long-term safety data can be col-
lected. Furthermore, serial amylase and
lipase measurements have been sug-
gested to predict the development of
acute pancreatitis (11).
In the Liraglutide Effect and Action in
Diabetes: Evaluation of cardiovascular
outcome Results (LEADER) trial, 9,340
patients with type 2 diabetes and high
cardiovascular risk were randomized to
the GLP-1 analog liraglutide or match-
ing placebo, both in addition to stan-
dard of care, and followed for 3.5–5.0
years. The aim of the current studywas to
evaluate results from LEADER regarding
the effects of liraglutide treatment on se-
rum lipase and amylase and the number
of cases of acute pancreatitis confirmed
by adjudication.
RESEARCH DESIGN AND METHODS
Detailed methods have previously been
published (12,13). Briefly, 9,340 patients
were enrolled at 410 sites in 32 countries.
Patients with type 2 diabetes at high risk
for cardiovascular events were random-
ized 1:1 double-blind to either subcutane-
ous liraglutide 1.8 mg daily (or maximum
tolerated dose) or placebo with a treat-
ment period of 3.5–5.0 years and a 30 day
follow-up period. Patients with a history
of pancreatitis were not excluded. The
primary composite outcome was the first
occurrence of death from cardiovascular
causes, nonfatal myocardial infarction, or
nonfatal stroke. Other prespecified out-
comes included acute pancreatitis.
Serum lipase and amylase (pancreas
specific) were measured at baseline and
months 6 and 12. Thereafter, assessments
were repeated annually until the trial
ended. No measurement was performed
after the planned end-of-treatment visit.
Serum pancreatic lipase and total amylase
were measured in the fasting state in all
patients using an enzymatic colorimetric
assay (Roche Diagnostics, Mannheim, Ger-
many) performed by a central laboratory
(ICON PLC, Dublin, Ireland). No patients
had symptoms suggesting acute pancrea-
titis at baseline blood draw. The upper
limit of normal (ULN) for the assays was
63 units/L for lipase and 100 units/L for
amylase. Neither limit was adjusted for
the distribution expected in patients with
type 2 diabetes. More frequent tests for
lipase and amylase were allowed at the
discretion of the investigator. Baseline li-
pase activity and amylase activity among
the study population have previously been
reported (14). Per protocol, participants
diagnosed with pancreatitis should be
withdrawn from study medication by
their care team.
Evaluation of Acute Pancreatitis
Pancreatitis was predefined by the trial
protocol as a medical event of special in-
terest. Revised Atlanta criteria were used
for a confirmeddiagnosis of acute pancre-
atitis and classified by severity (15)
(Supplementary Table 1). For the diagno-
sis of acute pancreatitis, two or more of
the following three criteria had to be ful-
filled: 1) severe acute upper abdominal
pain, 2) amylase and/or lipase threefold
or more above the ULN ($33 ULN), and
3) characteristic findings on imaging (ul-
trasound, computed tomography [CT], or
MRI) of thepancreas. Chronic pancreatitis
was defined by characteristic imaging
findings (ultrasound, CT, and MRI) with
abnormal pancreatic function tests or
characteristic histological findings. All po-
tential cases of pancreatitis were adjudi-
cated by an independent committee of
experts, which was blinded to treatment.
Toensure that potential events of pancre-
atitis were not missed for adjudication, a
Medical Dictionary for Regulatory Activi-
ties search of the clinical database was
performed to identify events for adjudi-
cation not already identified by study in-
vestigators. In those who developed
acute pancreatitis as confirmed by adju-
dication, data were further analyzed post
hoc as to whether gallstone disease was
present at the time of pancreatitis event
either on imaging (sonography, CT, MRI)
or blood testing (threefold elevation of
the liver enzyme profile alanine ami-
notransferase/aspartate transaminase)
(11). In addition, characteristics of the
events not confirmed by adjudication
were evaluated in a post hoc review by
the sponsor.
Statistical Analysis
All analyses were prespecified (before da-
tabase lock) unless marked otherwise.
Due to a right-skewed distribution, ob-
served geometric means for lipase and
amylase levels are presented. The differ-
ences between treatment groups in
lipase and amylase were estimated
using a mixed effects model for repeated
measurements adjusted for baseline co-
variates. Comparisons between groups
were performed at 36 months, as this
was the last annual visit with laboratory
testing for the majority of the patients,
given the minimum treatment period of
42 months. An analysis using a linear
model with repeated measures (Mixed
effect Model Repeat Measurement
[MMRM]) assuming an unstructured co-
variance matrix was performed to evalu-
ate the interaction between explanatory
factors at baseline and treatment in re-
lation to change from baseline for log-
transformed levels of lipase and amylase,
respectively, at each visit. Effects of each
level in the factors were presented as the
treatment ratio between liraglutide ver-
sus placebo at the 36-month visit. Explan-
atory factors were age, sex, BMI, smoking
status, diabetes duration, glycated hemo-
globin (HbA1c), baseline lipase and amy-
lase levels, medical history (including
history of pancreatitis), estimated glo-
merular filtration rate, lipid levels, and
use of certain medications. The interac-
tion between baseline characteristics
and allocated treatment (liraglutide vs.
placebo) on the development of acute
pancreatitis was examined using logistic
regression. Correction for multiple com-
parisons in the analyses of baseline char-
acteristics was performed using the
Bonferroni method.
The analyses for risk of acute pancrea-
titis were based on a Cox proportional
hazards model with treatment as a cova-
riate. All randomized patients were in-
cluded in the analyses, and patients
without acute pancreatitis were cen-
sored on the day of their follow-up visit/
withdrawal date or date of death. Events
occurring after follow-up visit were not
included. All analyses were performed
using SAS, version 9.3 (SAS Institute, Cary,
NC).
RESULTS
A total of 9,340 patients were random-
ized (4,668 to liraglutide and 4,672 to pla-
cebo, both added to standard of care). Of
these, 96.8% completed a final visit, died,
or had a primary outcome. The me-
dian and mean times of exposure to
study medication were 3.52 and 3.07
years, respectively. The mean proportion
of time on study drug was 84.0% for
liraglutide and 82.0% for placebo, and
71.3% of patients were exposed for 3–5
years. The median observation time was
3.84 years in both groups. The median
daily dose of liraglutide was 1.78 mg
(interquartile range 1.54–1.79) including
off-treatment periods. Of patients enter-
ing the study, 267 had a history of pan-
creatitis (147 and 120 in the liraglutide
and placebo groups, respectively).
Baseline Characteristics
Baseline population characteristics have
previously been published (13). The
mean age of the population was 64.3
years, 64.3% of the population were
male, and mean duration of diabetes
was 12.9 years.
Lipase and Amylase Levels Over Time
The time course andmagnitude of change
in lipase and amylase over time are de-
picted in Fig. 1 (13). In the liraglutide arm,
elevated levels of both enzymes were
seen at 6 months and persisted for the du-
ration of the study. Comparedwith placebo
and considering baseline characteris-
tics, at 36months liraglutidewasassociated
with an estimated relative 28.0% increase
in lipase (estimated treatment ratio 1.28
[95% CI 1.25–1.30; P , 0.001). Observed
mean lipase changed from 40.0 units/L
to 55.2 units/L for liraglutide. Similarly,
an estimated 7.0% (1.07 [95% CI 1.06–
1.09]; P, 0.001) increase in amylase was
seen with an observed amylase change
from 59.4 units/L to 70.9 units/L for
liraglutide. Results for both lipase andam-
ylase were similar when only patients
with an on-treatment laboratory value
were included (data not shown).
Figure 2 shows the categorical maxi-
mum values of lipase and amylase over
the course of the study. Of patients ran-
domized to liraglutide, 51.3% experi-
enced at least one elevated lipase level
(.ULN) over time compared with 31.8%
on placebo. In the liraglutide group, 8.3%
of patients and in the placebo group 5.3%
experienced increases of threefold or
more in lipase at some point during
the trial (Fig. 2). For amylase, 29.0% of
liraglutide-treated patients and 22.9% of
the placebo group had at least one ele-
vated amylase level during the study
(1.0% and 0.8%, respectively, had levels
elevated by threefold or more).
Effect of Baseline Data on Lipase
and Amylase Levels Over Time
The influenceof baseline characteristics on
increases in lipase andamylaseover time is
shown in Supplementary Table 2. With
adjustment for multiple comparisons,
only increased baseline lipase level was
found to have a statistically significant
positive association with subsequent ele-
vation of amylase.
Events Confirmed or Not Confirmed as
Acute Pancreatitis by the Adjudication
Process
Supplementary Table 3 presents details
of the adjudication process for Event Ad-
judication Committee confirmed acute
pancreatitis cases and which of the three
diagnostic criteria (typical pain, elevated
serum pancreatic enzymes $33 ULN,
and characteristic imaging findings) were
met. In all cases, aminimumof twoof these
three criteria were met.
Supplementary Tables 4–6 present
similar data for patients with events sug-
gestive of acute pancreatitis but in whom
the diagnosis of acute pancreatitis was not
confirmedby theadjudicationprocess. This
information is based on post hoc review by
the trial sponsor. The diagnosis was not
confirmed by the Event Adjudication Com-
mittee in 50 liraglutide-treated or 21 pla-
cebo patients. For themajority of events in
both treatment groups, patients had been
clinically evaluated due to any abdominal
painor elevation in lipaseor amylase levels.
Information on presence or absence of
pain, lipase and amylase levels, and imag-
ing was available in the majority of cases
but did not support a diagnosis of acute
pancreatitis. There was no imbalance in di-
agnostic procedures performed and infor-
mation available for the adjudication
process between patients administered
liraglutide or placebo.
Acute Pancreatitis
Acute pancreatitis events confirmed by ad-
judication were identified in 18 of the
4,668 liraglutide-treated patients (0.4%)
and 23 of the 4,672 placebo-administered
patients (0.5%) (Supplementary Table 7).
One of 18 patients in the liraglutide group
had 2 acute pancreatitis events (19 total
events), and8patients in theplacebogroup
had .1 event (31 total events) (Sup-
plementary Table 7). The corresponding
event rates were 1.1/1,000 PYO for the
liraglutide group and 1.7/1,000 PYO
for the placebo group (Supplementary
Table 7). When we analyzed first acute
pancreatitis events, there was a nonsignifi-
cant 22% reduction in the incidence (hazard
ratio 0.78 [95% CI 0.42–1.44]) (Fig. 3). Re-
sults were similar (hazard ratio 0.73 [95%
CI 0.35–1.54]) when only patients with
events that occurred during days on
treatment (+1 day) were included.
Figure 1—Lipase and amylase over time. Data are observed geometric means (full analysis
set) (12). Estimated treatment ratios were calculated using a mixed model for repeated measure-
ments. For amylase, 135 patients equally distributed between the liraglutide and placebo arms had
missing information and were not included in the analysis. For lipase, 177 patients had missing
information and were not included in the analysis. ETR, estimated treatment ratio; Lira, liraglutide;
U, units.
Most acute pancreatitis events were
mild according to modified Atlanta crite-
ria (89.5%and83.9% in the liraglutide and
placebo groups, respectively) (Supple-
mentary Tables 7 and 8). Six of the 18 pa-
tients in the liraglutide group had been
off liraglutide for extended periods of
time when the acute pancreatitis event
occurred (28, 30, 103, 146, 634, and
637 days, respectively) (Supplementary
Table 8). Gallstone disease was observed
(by imaging and/or $33 ULN elevations
of alanine aminotransferase/aspartate
transaminase) at the time of acute pan-
creatitis event for 7 of 18 (38.9%) com-
pared with 10 of 23 (43.5%) patients in
the liraglutide and placebo groups (P =
0.81) (Supplementary Table 8).
Two patients in the placebo group had
chronic pancreatitis events confirmed by
adjudication (Supplementary Table 7).
Figure 3 shows the time course of
acute pancreatitis events, which was sim-
ilar in both groups. No patients in the
liraglutide groupdevelopedacute pancre-
atitis within the first 6 months of therapy.
In both groups, most cases of acute pan-
creatitis developed.12months after be-
ginning the trial (Supplementary Table 8).
Of the patients who entered the trial with
a history of pancreatitis, 2 of 147 (1.4%) in
the liraglutide group and 6 of 120 (5.0%)
in the placebo group had another event
during the study.
Effect of Baseline Characteristics on
Subsequent Development of Acute
Pancreatitis
In Supplementary Table 9, the interaction
between baseline characteristics and
treatment on subsequent development
of acute pancreatitis is shown. There
was no statistically significant interaction
between liraglutide or placebo adminis-
tration and baseline characteristics on
the risk of emergent acute pancreatitis.
Predictive Value of Lipase and Amylase
Table 1 and Supplementary Tables 10 and
11 show the predictive values of measur-
ing lipase and amylase in predicting acute
pancreatitis. Whether the data were an-
alyzed using the .ULN or $33 ULN,
positive predictive values for elevated se-
rum levels of both enzymes was ,1.0%.
Supplementary Fig. 1 plots lipase and am-
ylase over time in patients who subse-
quently developed acute pancreatitis,
showing minimal elevations in levels
measured at scheduled visits prior to
the diagnosis of acute pancreatitis. Fi-
nally, in both the liraglutide and placebo
groups there was no association between
onefold or threefold elevated lipase and
the subsequent risk of acute pancreatitis
in patients without acute pancreatitis at
thetimeofmeasurement (Supplementary
Fig. 2). In fact, relatively more patients on
placebo had categorical increases in en-
zyme levels prior to the attack of acute
pancreatitis than for the liraglutide group,
albeit numbers were small.
CONCLUSIONS
This randomized, double-blind trial com-
paring liraglutide and placebo added to
standard of care in patients with type 2 di-
abetes and high cardiovascular risk is the
largest and longest study to date exposing
patients to the GLP-1 analog liraglutide. In
the present report, liraglutide treatment
was associated with a 28.0% increase in
mean serum lipase and 7.0% increase in
mean serum amylase compared with pla-
cebo. There were fewer acute pancreatitis
events in the liraglutide group, and isolated
liraglutide-associated elevations in lipase
and amylase were not predictive of subse-
quent acute pancreatitis. Liraglutide was
also associated with increases in the pro-
portion of patients with elevated enzyme
levels over the course of therapy, including
some with threefold or more increases in
lipase (albeit none of these had acute pan-
creatitis), findings consistent with prior
studies of liraglutide in patients with nor-
moglycemia, prediabetes, and diabetes
(16). The current study did not evaluate
pancreatic enzymes after liraglutide was
discontinued, but prior work has shown
that serum pancreatic enzymes return
to baseline when liraglutide is stopped
(17).
The cause of serum pancreatic enzyme
elevations, especially lipase, induced by
liraglutide is unknown. Indeed, themech-
anisms by which pancreatic enzymes en-
ter and exit the blood compartment have
not been elucidated. One hypothesis is
that enzymes enter the blood by passing
through the basolateral membrane of the
acinar cell allowing access into the blood
(“spillover” of a minor percentage of the
Figure 3—Time to confirmed acute pancreatitis. Kaplan-Meier plot of confirmed acute pancreatitis
first index events (full analysis set). Values underneath the graph are number of subjects at risk. HR,
hazard ratio; Lira, liraglutide.
Figure 2—Maximum lipase and amylase levels by category. Data are presented as proportion of
subjects with maximum lipase and amylase levels at scheduled measurements within the stated
categories (.ULN, $23 ULN, or$33 ULN [full analysis set]).
enzymespresent in acinar cells). The elim-
ination of lipase from the blood is thought
in part to be due to renal degradation of
the enzyme (18). Although previous stud-
ies reported controversial views on
whether human pancreatic acinar cells
express GLP-1 receptors (19,20), recent
animal studies indicate that pancreatic
acinar cells have GLP-1 receptors that,
when stimulated, increase the production
and secretion of pancreatic enzymes (20).
However, increases in pancreatic secre-
tion into the pancreatic ductular system
and intestine alone do not explain higher
levels in the blood. Along these lines, se-
rum pancreatic enzymes do not rise
after a meal despite an increase in pan-
creatic secretion (21). It appears possible
that liraglutide somehow enhances the
basolateral secretion of pancreatic en-
zymes, especially lipase, into the blood
or may affect the degradation of lipase
in the kidney. Alternative explanations
are an increase in pancreatic exocrine
weight due to stimulation of protein syn-
thesis, as shown in rodents treated with
liraglutide, with a likely stimulation of
pancreatic enzyme synthesis as part of
this general enhancement in protein syn-
thesis (22), although similar effects have
not been obvious in studying nonhuman
primates (23). The changes in lipase and
amylase may also be the consequence of
changes in food preferences (as part of
well-established reductions in appetite
and caloric intake induced by liraglutide)
(24,25) leading to altered expression of
pancreatic enzymes specifically favoring
the digestion of preferred substrates
(26–28). Altogether, the mechanism of
GLP-1 receptor stimulationwith liraglutide
on serum lipase (and, less so, amylase) has
not been sufficiently delineated.
Despite this background of increased li-
pase and amylase associated with liraglutide,
the rate of acute pancreatitiswas quite low
overall and 22% lower in the liraglutide
than in the placebo group, albeit not statis-
tically significant. The liraglutide group
also included six patients who were off
liraglutide for 28–637 days when acute
pancreatitis developed. The relationship
between acute pancreatitis and drugs
that have been stopped for long periods
of time remains obscure. In pooled data
from prior studies of the GLP-1 receptor
agonists exenatide, liraglutide, and lixise-
natide, an excess of acute pancreatitis was
found compared with comparator treat-
ments (2.1/1,000 PYO and 1.5/1,000
PYO, respectively) (8). The lower event
rate for acute pancreatitis in the current
study (1.1/1,000 PYO) compared with the
rate reported in the analysis byMeier and
Nauck (8) may be the result of adjudica-
tion in the current study; adjudicationwas
not performed in all studies contributing
to the pooled analysis.
The current study population consisted
of patients with type 2 diabetes at high
risk for cardiovascular events, which is
different from populations previously
studied. Interestingly, another recent
cardiovascular outcomes trial for the
once-weekly GLP-1 analog semaglutide
reported a lower number of patients
with acute pancreatitis events in the sem-
aglutide versus placebo group (9 and
12 for semaglutide and placebo, respec-
tively), as confirmed by adjudication (29).
Similarly, the cardiovascular outcomes tri-
al for the short-acting GLP-1 receptor
agonist lixisenatide reported five and eight
patients with acute pancreatitis in the lix-
isenatide and placebo groups, respectively
(30). Additional cardiovascular outcomes
trials for other GLP-1 receptor agonists
are expected to report in the coming
years and may provide further data on
this topic.
The time course of acute pancreatitis in
both liraglutide and placebo groups was
similar. The majority of patients in both
groups had acute pancreatitis attacks after
participating in the trial for .12 months.
Most therapies associated with drug-
induced pancreatitis are thought to be
due to a hypersensitivity reaction (31).
Hypersensitivity reactions tend to have
much shorter latencies (the time interval
between starting the drug and develop-
ment of acute pancreatitis) of up to
12 weeks (32,33). Long latencies as seen
in the present population suggest a differ-
ent mechanism than hypersensitivity. An-
other possibility is the development of
gallstones leading to gallstone pancreati-
tis. Patients with type 2 diabetes (not on
GLP-1 receptor agonists) have an in-
creased risk of developing gallstones
and acute pancreatitis (6), and liraglutide
therapy in patients without diabetes in-
creases the risk of gallstones and acute
cholecystitis compared with placebo
(34). Gallstones may take an extended
period of time to form,whichmay explain
the latency between drug initiation and
acute pancreatitis in some patients. In
LEADER, an increased risk of develop-
ment of acute gallstone disease was
also observed in the liraglutide group
compared with placebo (3.1% vs. 1.9%,
P , 0.001) (13). Nevertheless, the ob-
served imbalance in acute gallstone dis-
ease did not translate into an increased
risk of gallstone-associated acute pancre-
atitis, since a similar proportionof pancre-
atitis events (38.9% vs. 43.5%) was found
to be associated with signs of gallstone
disease being present at the time of
event in the liraglutide group compared
with placebo. The protocol required all
adverse events of acute gallstone disease
to be reported; however, asymptom-
atic gallstones were not required to be
reported, and furthermore, systematic
clinical evaluation for gallstone disease
at baseline in the LEADER trial was not
part of the protocol.
It has been suggested that liraglutide
may induce pancreatitis in patients with
prior history of pancreatitis (35). In fact,
Table 1—Predictive value of increased lipase or amylase levels for confirmed acute
pancreatitis
Liraglutide Placebo
N % N %
Lipase .ULN during trial 2,604 1,682
Subsequent acute pancreatitis 7 0.27 11 0.65
Lipase $33 ULN during trial 339 216
Subsequent acute pancreatitis 0 0.00 2 0.93
Amylase .ULN during trial 1,382 1,084
Subsequent acute pancreatitis 3 0.22 5 0.46
Amylase $33 ULN during trial 38 35
Subsequent acute pancreatitis 0 0.00 0 0.00
Data are for confirmed acute pancreatitis (full analysis set). Subjects are included in the elevated
lipase or amylase category from the date of first elevation within the stated categories (.ULN
and$33 ULN lipase or amylase). Hazard ratios and 95% CIs derived from data in this table are
shown in Supplementary Fig. 2. %, percentage of subjects; N, number of subjects.
prescribing information for liraglutide ad-
vises exercising caution in patients with a
history of acute pancreatitis and that
other therapies should be considered. In
the current study, pancreatitis was not an
exclusion criterion for study entry, and in
patients with prior history of pancreatitis,
only 2 of 147 (1.4%) in the liraglutide
group and 6 of 120 (5.0%) in the placebo
group developed acute pancreatitis. Our
results do not support the exclusion of
patients with previous pancreatitis from
treatmentwithGLP-1 receptor agonists in
general terms and with liraglutide in par-
ticular. Nevertheless, the study protocol
did not call for an active investigation to
characterize previous pancreatic or biliary
structural or functional damage.
The U.S. Food and Drug Administration
and other regulatory authorities have
mandated that studies involvingGLP-1 re-
ceptor agonists monitor lipase and amy-
lase levels under the assumption that this
might predict patients’ development of
acute pancreatitis. This study and others
(16) have shown that the positive predic-
tive value of an isolated elevation of these
enzymes for acute pancreatitis is very low
(,1.0%). Indeed, in the population of all
patients treated with liraglutide in the
LEADER trial who developed substantially
elevated serum lipase ($33 ULN) while
beingasymptomatic, nonedevelopedacute
pancreatitis later in the trial. In fact, among
patientswith categorical enzymeelevations
there were relatively more in the placebo
group who subsequently developed acute
pancreatitis (basedonsmall numbers) (Sup-
plementary Fig. 2). The reasons for this
remain obscure.
The present analysis provides details
on the blinded adjudication process
(Supplementary Tables 3–6) that demon-
strate sufficient data were available for ei-
ther confirming or refuting the diagnosis of
acute pancreatitis for those events that
were adjudicated. These data also show
that despite more suspected events sent
for adjudication with liraglutide treatment
(most likely due to lipase and amylase in-
creases as well as abdominal pain) versus
placebo, among thoseeventsnot confirmed
by adjudication, the extent of workup was
similar between the two groups.
Strengths of the current study include
its large population, placebo-controlled
design, and relatively long-term observa-
tion time (for a minimum of 3.5 and up to
5.0 years). Serum samples were collected
prospectively at specified intervals.
Finally, to ensure objective assessment
of events of suspected acute pancreatitis,
a committee blinded to treatment evalu-
ated all cases andused theAtlanta criteria
to confirm a diagnosis of acute pancrea-
titis. A potential weakness of this study is
that the trial population only included pa-
tients with type 2 diabetes, the majority
being men, with a higher mean age and
longer diabetes duration than the wider
population of patients with type 2 diabe-
tes. Thus, our findings may not be gener-
alizable. Another potential limitation is
the low number of acute pancreatitis
events, which leads to wide CIs, meaning
that we cannot completely rule out a po-
tential increased risk (Fig. 3). Finally,
because patients could discontinue treat-
ment or not reach the 36-month visit (if
they discontinued the trial or died), the re-
lationship between lipase levels and pan-
creatitis events could be diluted and/or
the association between liraglutide treat-
ment and risk of acute pancreatitis could
be affected. However, analyses that in-
cluded only the on-treatment population
showed similar results to those of the in-
tention-to-treat analyses, potentially due to
the high degree of exposure in the trial.
In summary, this study confirmed and
extended observations concerning the ef-
fect of liraglutide on the pancreas. In
LEADER, numerically fewer events of
acute pancreatitis were observed in
liraglutide-treated patients compared
with the placebo group. Liraglutide in-
creased serum amylase, and especially li-
pase, and this increase plateaued and
remained stable for the duration of the
study. Liraglutide-induced elevations
of lipase and amylase in asymptomatic
patients were not predictive of the de-
velopment of acute pancreatitis.
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